Tarvacin (bavituximab) / OncXerna Therap 
Welcome,         Profile    Billing    Logout  
 58 Diseases   2 Trials   2 Trials   158 News 


«123»
  • ||||||||||  Tarvacin (bavituximab) / Oncologie, 2aG4 / Peregrine
    Activation of toll-like receptors via PS-targeting monoclonal antibodies (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_703;    
    Overall these data support that one mechanism of innate immune activation induced by PS-targeting mAbs is through TLR2 stimulation on myeloid cells. Future studies are focused on validating these results in vivo using Tlr-deficient and b2gp1-deficient mice.
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Trial completion date, Trial primary completion date:  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  May 24, 2019   
    P2,  N=36, Active, not recruiting, 
    Further clinical investigation would be necessary to better define the efficacy of this combination. Trial completion date: Jul 2023 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 17, 2018   
    P1,  N=0, Withdrawn, 
    Trial completion date: Feb 2016 --> Oct 2018 N=18 --> 0 | Trial completion date: Jan 2021 --> Oct 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2020 --> Oct 2018
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Oct 12, 2018   
    P1/2,  N=49, Completed, 
    N=18 --> 0 | Trial completion date: Jan 2021 --> Oct 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2020 --> Oct 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Apr 2018 | Trial primary completion date: Dec 2016 --> Apr 2018
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Oct 5, 2018   
    P2,  N=36, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Apr 2018 | Trial primary completion date: Dec 2016 --> Apr 2018 Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Jul 2023 | Trial primary completion date: Dec 2020 --> Jul 2019
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Enrollment change, Trial withdrawal, Metastases:  Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) -  Jul 11, 2017   
    P2/3,  N=0, Withdrawn, 
    Overall, these results strongly support the combination of bavituximab with sorafenib as a promising systemic therapeutic strategy for the treatment for advanced HCC patients. N=148 --> 0 | Suspended --> Withdrawn
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Enrollment open:  Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 29, 2017   
    P1,  N=18, Recruiting, 
    This regimen is being evaluated in the ongoing, global, phase III SUNRISE trial. Not yet recruiting --> Recruiting
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap, Yervoy (ipilimumab) / BMS
    Phase classification, Enrollment change, Trial termination, Metastases:  A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (clinicaltrials.gov) -  Dec 29, 2016   
    P1b,  N=3, Terminated, 
    Active, not recruiting --> Completed Phase classification: P1 --> P1b | N=24 --> 3 | Active, not recruiting --> Terminated; standard of care improved combination treatment of ipilimumab plus nivolumab.
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Trial primary completion date, Metastases:  Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Jun 1, 2016   
    P1/2,  N=56, Active, not recruiting, 
    N=198 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) -  Apr 21, 2016   
    P1,  N=14, Completed, 
    Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> May 2013
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Trial primary completion date, Metastases:  Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Jan 5, 2015   
    P1/2,  N=56, Active, not recruiting, 
    Trial primary completion date: Aug 2015 --> Jun 2016 Trial primary completion date: Dec 2014 --> Dec 2015
  • ||||||||||  Tarvacin (bavituximab) / OncXerna Therap
    Enrollment closed, Metastases:  Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Oct 11, 2014   
    P1/2,  N=56, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2014 Recruiting --> Active, not recruiting
  • ||||||||||  anti-phosphatidylserine monoclonal antibodies / Avid Bioservices, Affitech, Tarvacin (bavituximab) / OncXerna Therap
    Trial completion, Metastases:  Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) -  Feb 22, 2014   
    P1,  N=28, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  anti-phosphatidylserine monoclonal antibodies / Avid Bioservices, Affitech, Tarvacin (bavituximab) / OncXerna Therap
    Trial completion:  Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) -  Feb 22, 2014   
    P1,  N=32, Completed, 
    Active, not recruiting --> Completed No longer recruiting --> Completed